MetaCap

Bambusa Therapeutics (BBTX) vs Monte Rosa Therapeutics (GLUE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bambusa Therapeutics is the larger company by market cap ($815.1 million vs $738.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BBTX+6.74%GLUE-19.70%
+16%-3%-21%
Oct 30, 20261 yearNov 20, 2026
BBTX+6.74%GLUE-19.70%
+9%-6%-21%
Oct 26, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BBTX versus GLUE key metrics
MetricBBTXGLUE
Share price$16.00$8.64
Market cap$815.08M$738.29M
1-day change+2.89%-3.03%
YTD return—-44.90%
1-year return—-39.24%
5-year return—-57.96%
EPS (TTM)$-1.73$-1.39
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$123.67M
Revenue growth (YoY)—+63.54%
Net income (latest FY)—$-38.60M
Operating margin—-43.83%
Net margin—-31.21%
52-week high$17.65$25.77
52-week low$13.60$8.48
Distance from 52-week high-9.35%-66.47%
Analyst consensus—strong_buy
Avg. price target upside—+193.75%
Average volume359.41K1.37M
Shares outstanding50.94M85.45M
Employees26185
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Bambusa Therapeutics

BBTX stock →

Bambusa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops long-acting bispecific antibodies for the treatment of immunological and inflammatory disorders. The company develops BBT001 for Type 2 inflammatory dermatological conditions, including atopic dermatitis, chronic spontaneous urticaria, and prurigo nodularis.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 26 employees

About Monte Rosa Therapeutics

GLUE stock →

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 185 employees

BBTX vs GLUE FAQ

Which is bigger, Bambusa Therapeutics or Monte Rosa Therapeutics?

Bambusa Therapeutics (BBTX) is larger, with a market capitalization of $815.08M compared with $738.29M for Monte Rosa Therapeutics (GLUE).

Are Bambusa Therapeutics and Monte Rosa Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons